Deals in Depth: February 2010
Executive Summary
Overall alliance money was low in comparison to January, with no deals rising over the $150mm potential deal value mark. Standing out were GSK's microRNA collaboration with Regulus that could be worth up to $150mm. M&A activity was led, by far, by Merck KGAA's $7.2bn takeover of life sciences company Millipore. Biopharma financing dollars fell in comparison to January numbers, while device financing totals came in higher.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.